Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.43 |
| ▸ | FAP | Q12884 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260364 | 0.88 | DPP4 (0.43) | DPP4DPP7FAPALDH1A1KDM4E | |
| SCHEMBL14557987 | 0.87 | DPP4 (0.42) | DPP4DPP7FAPSMN1; SMN2DPP8 | |
| SCHEMBL24260448 | 0.85 | DPP4 (0.46) | DPP4DPP7FAPALDH1A1DPP8 | |
| SCHEMBL24260146 | 0.80 | DPP4 (0.41) | DPP4DPP7FAPALDH1A1DPP8 | |
| SCHEMBL3253522 | 0.79 | DPP4 (0.47) | DPP4DPP7FAPSMN1; SMN2DPP8 | |
| SCHEMBL24260440 | 0.77 | DPP4 (0.39) | DPP4DPP7FAPALDH1A1KDM4E | |
| SCHEMBL14186210 | 0.77 | DPP4 (0.46) | DPP4DPP7FAPPOLBL3MBTL1 | |
| SCHEMBL14569490 | 0.75 | HCRTR2 (0.44) | SMN1; SMN2 | |
| SCHEMBL24260592 | 0.74 | POLB (0.40) | DPP4DPP7FAPALDH1A1KDM4E | |
| SCHEMBL14259818 | 0.73 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | DPP4 288/4885DPP7 2872/4885FAP 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.